Berberine Down-Regulated Myostatin Expression and Facilitated Metabolism via Smad Pathway in Insulin Resistant Mice

References

• Jheng JR, Chen YS, Ao UI, et al. The double-edged sword of endoplasmic reticulum stress in uremic sarcopenia through myogenesis perturbation: ER stress in uremic sarcopenia. J Cachexia Sarcopenia Muscle. 2018;9(3):570–584. doi:10.1002/jcsm.12288
   PubMedGoogle Scholar
• Bischoff-Ferrari HA, Orav JE, Kanis JA, et al. Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older. Osteoporos Int. 2015;26(12):2793–2802. doi:10.1007/s00198-015-3194-y
   PubMed Web of Science ®Google Scholar
• Beaudart C, Biver E, Reginster JY, et al. Validation of the SarQoL(R), a specific health-related quality of life questionnaire for Sarcopenia. J Cachexia Sarcopenia Muscle. 2017;8(2):238–244. doi:10.1002/jcsm.12149
   PubMed Web of Science ®Google Scholar
• De Buyser SL, Petrovic M, Taes YE, et al. Validation of the FNIH sarcopenia criteria and SOF frailty index as predictors of long-term mortality in ambulatory older men. Age Ageing. 2016;45:602–608. doi:10.1093/ageing/afw071
   PubMedGoogle Scholar
• Kim TN, Park MS, Lim KI, et al. Relationships between sarcopenic obesity and insulin resistance,inflammation, and vitamin D status: the Korean Sarcopenic Obesity Study. Clin Endocrinol (Oxf). 2013;78:525–532. doi:10.1111/j.1365-2265.2012.04433.x
   PubMed Web of Science ®Google Scholar
• Petta S, Ciminnisi S, Di Marco V, et al. Sarcopenia is associated with severe liver fibrosis in patients with non‐alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017;45:510–518. doi:10.1111/apt.13889
   PubMed Web of Science ®Google Scholar
• Han E, Lee YH, Kim G, et al. Sarcopenia is associated with albuminuria independently of hypertension and diabetes: KNHANES 2008–2011. Metabolism. 2016;65(10):1531–1540. doi:10.1016/j.metabol.2016.07.003
   PubMed Web of Science ®Google Scholar
• Patel HP, Al-Shanti N, Davies LC, et al. Lean mass, muscle strength and gene expression in community dwelling older men: findings from the Hertfordshire Sarcopenia Study (HSS). Calcif Tissue Int. 2014;95(4):308–316. doi:10.1007/s00223-014-9894-z
   PubMed Web of Science ®Google Scholar
• Arounleut P, Bialek P, Liang LF, et al. A myostatin inhibitor (propeptide-Fc) increases muscle mass and muscle fiber size in aged mice but does not increase bone density or bone strength. Exp Gerontol. 2013;48:898–904.
   PubMed Web of Science ®Google Scholar
• Xin XB, Yang SP, Li X, et al. Proteomics insights into the effects of MSTN on muscle glucose and lipid metabolism in genetically edited cattle. Gen Comp Endocrinol. 2020;291:113237. doi:10.1016/j.ygcen.2019.113237
   PubMedGoogle Scholar
• Liu XH, Bauman WA, Cardozo CP. Myostatin inhibits glucose uptake via suppression of insulin-dependent and independent signaling pathways in myoblasts. Physiol Rep. 2018;17:e13837.
   Google Scholar
• Hu X, Zhang Y, Xue Y, Zhang Z, Wang J. Berberine is a potential therapeutic agent for metabolic syndrome via brown adipose tissue activation and metabolism regulation. Am J Transl Res. 2018;10:3322–3329.
   PubMed Web of Science ®Google Scholar
• Pirillo A, Catapano AL. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence to clinical studies. Atherosclerosis. 2015;243:449–461. doi:10.1016/j.atherosclerosis.2015.09.032
   PubMed Web of Science ®Google Scholar
• Yu Y, Zhao Y, Teng F, et al. Berberine improves cognitive deficiency and muscular dysfunction via activation of the AMPK/SIRT1/PGC-1a pathway in skeletal muscle from naturally aging rats. J Nutr Health Aging. 2018;22(6):710–717. doi:10.1007/s12603-018-1015-7
   PubMed Web of Science ®Google Scholar
• Wu YY, Zha Y, Liu J, et al. Effect of berberine on the ratio of high-molecular weight adiponectin to total adiponectin and adiponectin receptors expressions in high-fat diet fed rats. Chin J Integr Med. 2016. doi:10.1007/s11655-016-2518-x
   Google Scholar
• Zhang DS, Bai XH, Yao YJ, Mu DZ, Chen J. Effect of berberine on the insulin resistance and TLR4/IKKbeta/NF-kappaB signaling pathways in skeletal muscle of obese rats with insulin resistance. Sichuan Da Xue Xue Bao Yi Xue Ban. 2015;46:827–831.
   PubMedGoogle Scholar
• Zhang Q, Xiao X, Feng K, et al. Berberine moderates glucose and lipid metabolism through multipathway mechanism. Evid Based Complement Alternat Med. 2011;2011:1–10. doi:10.1155/2011/924851
   Web of Science ®Google Scholar
• Hittel DS, Axelson M, Sarna N, Shearer J, Huffman KM, Kraus WE. Myostatin decreases with aerobic exercise and associates with insulin resistance. Med Sci Sports Exerc. 2010;42:2023–2029.
   PubMed Web of Science ®Google Scholar
• Nagy C, Einwallner E. Study of in vivo glucose metabolism in high-fat diet-fed mice using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT). J Vis Exp. 2018;131:56672.
   Google Scholar
• Zhang C, McFarlane C, Lokireddy S, et al. Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway. Diabetologia. 2011;54(6):1491–1501. doi:10.1007/s00125-011-2079-7
   PubMed Web of Science ®Google Scholar
• Cleasby ME, Jarmin S, Eilers W, et al. Local overexpression of the myostatin propeptide increases glucose transporter expression and enhances skeletal muscle glucose disposal. Am J Physiol Endocrinol Metab. 2014;306(7):E814–E823. doi:10.1152/ajpendo.00586.2013
   PubMedGoogle Scholar
• Zhu S, Tian Z, Torigoe D, et al. Aging- and obesity-related peri-muscular adipose tissue accelerates muscle atrophy. PLoS One. 2019;14(8):e0221366. doi:10.1371/journal.pone.0221366
   PubMedGoogle Scholar
• Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–1830.
   PubMed Web of Science ®Google Scholar
• Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev. 2007;21(12):1443–1455. doi:10.1101/gad.1550907
   PubMed Web of Science ®Google Scholar
• Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17:4–12.
   PubMed Web of Science ®Google Scholar
• Kalinkovich A, Livshits G. Sarcopenic obesity or obese sarcopenia: a cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis. Ageing Res Rev. 2017;35:200–221. doi:10.1016/j.arr.2016.09.008
   PubMed Web of Science ®Google Scholar
• Watts R, McAinch AJ, Dixon JB, O’Brien PE, Cameron-Smith D. Increased Smad signaling and reduced MRF expression in skeletal muscle from obese subjects. Obesity (Silver Spring). 2013;21(3):525–528. doi:10.1002/oby.20070
   PubMedGoogle Scholar
• Fuentes EN, Pino K, Navarro C, Delgado I, Valdés JA, Molina A. Transient inactivation of myostatin induces muscle hypertrophy and overcompensatory growth in zebrafish via inactivation of the SMAD signaling pathway. J Biotechnol. 2013;168(4):295–302. doi:10.1016/j.jbiotec.2013.10.028
   PubMedGoogle Scholar
• Retamales A, Zuloaga R, Valenzuela CA, Gallardo-Escarate C, Molina A, Valdés JA. Insulin-like growth factor-1 suppresses the Myostatin signaling pathway during myogenic differentiation. Biochem Biophys Res Commun. 2015;464(2):596–602. doi:10.1016/j.bbrc.2015.07.018
   PubMed Web of Science ®Google Scholar
• Liu XH, Bauman WA, Cardozo CP. Myostatin inhibits glucose uptake via suppression of insulin-dependent and -independent signaling pathways in myoblasts. Physiol Rep. 2018;6:e13837.
   PubMed Web of Science ®Google Scholar